Copyright
©The Author(s) 2019.
World J Gastroenterol. Aug 7, 2019; 25(29): 3897-3919
Published online Aug 7, 2019. doi: 10.3748/wjg.v25.i29.3897
Published online Aug 7, 2019. doi: 10.3748/wjg.v25.i29.3897
Table 4 Recommended preferred treatment regimens for hepatitis C virus GT2 infection
| Recommendation category | Treatment option(s) | Treatment regimen |
| Preferred | SOF + DCV ± RBV | SOF + DCV for 12 wk in noncirrhotics |
| In decompensated cirrhosis and previous failures: | ||
| SOF + DCV + RBV for 12 wk | ||
| SOF + RBV | SOF + RBV for 12 wk in noncirrhotics | |
| To be extended to 24 wk in cirrhotics and treatment failures (Data are not available for patients with decompensated cirrhosis.) | ||
| Should be considered as an alternative regimen when DCV is not available | ||
| Not recommended | Due to the advent of newer DAAs, pegylated interferon, boceprevir, and telaprevir-based regimens are not recommended. | |
- Citation: Colombo MG, Musabaev EI, Ismailov UY, Zaytsev IA, Nersesov AV, Anastasiy IA, Karpov IA, Golubovska OA, Kaliaskarova KS, AC R, Hadigal S. Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions. World J Gastroenterol 2019; 25(29): 3897-3919
- URL: https://www.wjgnet.com/1007-9327/full/v25/i29/3897.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i29.3897